시장보고서
상품코드
1089969

고효능 API 시장 규모, 점유율, 동향 분석 : 종류별, 합성별, 제조업체별, 용도별, 지역별 전망, 경쟁 전략, 부문별 예측(-2030년)

High Potency APIs Market Size, Share & Trends Analysis By Type, By Synthesis, By Manufacturers, By Application, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

발행일: | 리서치사: SPER Market Research Pvt. Ltd. | 페이지 정보: 영문 223 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 고효능 API 시장 규모는 향후 6.9%의 CAGR로 확대되고, 2030년까지 370억 달러에 달할 것으로 예측됩니다. 종양 치료제 요구 확대, 항체 약물 접합체 채용 증가, 고효능 API에 관한 대형 제약회사의 주목 상승, 고효능 API 제조 방법의 개발, 정밀의료에 대한 주목 상승 등이 이 시장을 촉진하는 주요 요인이 되고 있습니다.

세계의 고효능 API(High Potency APIs) 시장에 대해 조사했으며, 시장 개요와 함께 종류별, 합성별, 제조업체별, 용도별, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 성장 촉진요인, 성장 억제요인, 기회, 과제 분석
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 과제
  • COVID-19가 고효능 API 시장에 미치는 영향

제5장 시장 변수와 전망

  • SWOT 분석
  • PESTEL 분석
  • Porter's Five Forces 분석
  • 히트맵 분석

제6장 세계의 고효능 API 시장, 종류별, 2019-2030년(100만 달러)

  • 서론
  • 혁신적 고효능 API
  • 일반적 고효능 API

제7장 세계의 고효능 API 시장, 합성별, 2019-2030년(100만 달러)

  • 서론
  • 합성 API
  • 바이오테크놀러지 API

제8장 세계의 고효능 API 시장, 제조업체별, 2019-2030년(100만 달러)

  • 서론
  • 캡티브 제조업체
  • 머천트 제조업체

제9장 세계의 고효능 API 시장, 용도별, 2019-2030년(100만 달러)

  • 서론
  • 종양학
  • 호르몬 밸런스 이상
  • 녹내장
  • 기타

제10장 세계의 고효능 API 시장, 지역별, 2019-2030년(100만 달러)

  • 북미
  • 유럽
  • 아시아태평양
  • 남미
  • 중동 및 아프리카

제11장 기업 개요

  • AbbVie
  • Albany Molecular Research Inc.
  • BASF SE
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Carbogen Amcis
  • Cipla Inc.
  • Corden Pharma International
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Lonza
  • Merck & Co., Inc
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Viatris Inc.
KSM 22.06.28

High Potency APIs Market is projected to be worth USD 37.0 billion by 2030.

According to SPER Market Research, High Potency APIs Market is estimated to reach USD 37.0 billion by 2030 with a CAGR of 6.9%. Expanding need for oncology medications, increasing adoption for antibody-drug conjugates, increased attention of prominent pharmaceutical companies on High Potency APIs, developments in High Potency APIs manufacturing methods, and growing focus on precision medicine are all driving this market forward.

Impact of COVID-19 on the High Potency APIs Market

High Potency APIs market was negatively impacted by the COVID-19 outbreak. COVID-19 significantly impacted this market supply chain. The economic scenario induced by the COVID-19 pandemic in 2020 has hindered the development of this market severely. As the share of enterprises outsourcing to countries with low-cost production technology grows at a rapid rate, companies are expected to benefit.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Type, By Synthesis, By Manufacturers, By Application
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered

AbbVie, Albany Molecular Research Inc., BASF SE, Bayer AG, Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Company, Carbogen Amcis, Cipla Inc., CordenPharma International, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche, Lonza, Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc.

Driver: Rising demand for cancer medications

Rising cancer medicine demand is expected to open up a wide range of prospects in the worldwide High Potency API market. High Potency APIs are highly effective pharmacologically active compounds that provide significant action and efficiency even at low dosages. Because of the increasing incidence and prevalence of cancer, there is an increase in need for more effective cancer therapies, such as High Potency APIs. To meet the rising demand, pharmaceutical companies such as Pfizer, Sanofi, F. Hoffmann-La Roche, and others are putting more effort into developing pipelines for innovative cancer therapies.

Restraint: Cross-contamination is a major concern

Cross-contamination is one of the most serious concerns connected with High Potency API production. Mounting emphasis on the pharmaceutical business to minimise costs and make biopharmaceuticals more affordable to users are important factors encouraging the industry to use as many effective and efficient multi-product and multi-purpose facilities as possible. High Potency APIs frequently demonstrate high cytotoxicity in addition to high potency, so measures to minimise cross-contamination are critical to a safe production process that ensures the wellness of staff, the surroundings, and the patient.

Opportunity: Opportunities for CMOs and CDMOs are expanding

A complete High Potency API production plant necessitates thorough planning, the use of risk mitigation and assessment techniques, and a process for determining which compounds are eligible for production in each facility. The manufacture of such chemicals is hazardous to employees and the environment. Pharmaceutical companies must also be able to safely produce, store, and transport a growing number of strong substances. This demonstrates that building an effective High Potency API production plan necessitates substantial time and investment. As a result, many sponsor firms choose to seek assistance from CMOs and CDMOs for the development, production, and distribution of High Potency APIs and their formulated medicinal products, as some of these organizations have the proper equipment.

Challenges: Processes must be designed correctly

Among the most important needs for High Potency API production process is process design. The majority of High Potency APIs must be manufactured in tiny clinical and commercial quantities. However, producing gram scale GMP APIs and payloads is difficult. Ensuring containment control while using flexible and tiny equipment, especially glass equipment, is a significant problem that necessitates a customised method for each process and unit operation. It is also critical to retain proper process designs at the developmental size to guarantee that the process suits the plant equipment and capacities when scaled up. Furthermore, there is confusion in the business regarding the types of High Potency APIs. Because of an insufficient data, the classification of new APIs is uncertain due to the use of proprietary systems by various pharmaceutical corporations. These problems can be avoided with proper process designs and containment controls, which most businesses lack. All of these reasons, taken together, are expected to pose a considerable challenge to High Potency API market participants.

Global High Potency APIs Market, By Type:

Based on the Type, Global High Potency APIs Market is segment as; Innovative High Potency APIs, Generic High Potency APIs.

Global High Potency APIs Market, By Synthesis:

Based on the Synthesis, Global High Potency APIs Market is segment as; Synthetic APIs (Synthetic APIs Market By Type), Biotech APIs (Biotech APIs Market By Type, Biotech APIs Market By Product, Vaccines, Recombinant Proteins).

Global High Potency APIs Market, By Manufacturer:

Based on the Manufacturer, Global High Potency APIs Market is segment as; Captive High Potency APIs Manufacturers, Merchant High Potency APIs Manufacturers (Merchant High Potency APIs Manufacturers Market By Type, Merchant High Potency APIs Manufacturers Market By Type of Synthesis, Synthetic APIs, Biosynthetic APIs).

Global High Potency APIs Market, By Application:

Based on the Application, Global High Potency APIs Market is segment as; Oncology, Hormonal Imbalance, Glaucoma, Other Therapeutic Applications.

Global High Potency APIs Market, By Region:

North America owns the prime share of this market; this is due to the increasing prevalence of cancer, also China is growing faster in the Asia-Pacific region.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the High Potency APIs Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global High Potency APIs Market, By Type, 2019-2030 (USD Million)

  • 6.1. Introduction
  • 6.2. Innovative High Potency APIs
  • 6.3. Generic High Potency APIs

7. Global High Potency APIs Market, By Synthesis, 2019-2030 (USD Million)

  • 7.1. Introduction
  • 7.2. Synthetic APIs
    • 7.2.1. Synthetic APIs Market, By Type
  • 7.3. Biotech APIs
    • 7.3.1 Biotech APIs Market, By Type
    • 7.3.2 Biotech APIs Market, By Product
    • 7.3.3 Vaccines
    • 7.3.4 Recombinant Proteins

8. Global High Potency APIs Market, By Manufacturer, 2019-2030 (USD Million)

  • 8.1. Introduction
  • 8.2. Captive High Potency APIs Manufacturers
  • 8.3. Merchant High Potency APIs Manufacturers
    • 8.3.1 Merchant High Potency APIs Manufacturers Market, By Type
    • 8.3.2 Merchant High Potency APIs Manufacturers Market, By Type of Synthesis
    • 8.3.3 Synthetic APIs
    • 8.3.4 Biosynthetic APIs

9. Global High Potency APIs Market, By Application, 2019-2030 (USD Million)

  • 9.1. Introduction
  • 9.2. Oncology
  • 9.3. Hormonal Imbalance
  • 9.4. Glaucoma
  • 9.5. Other Therapeutic Applications

10. Global High Potency APIs Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. AbbVie
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Albany Molecular Research Inc.
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. BASF SE
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Bayer AG
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Boehringer Ingelheim International GmbH.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Bristol-Myers Squibb Company
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Carbogen Amcis
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Cipla Inc.
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Corden Pharma International
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. Dr. Reddy's Laboratories Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Eli Lilly and Company
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. F. Hoffmann-La Roche
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Lonza
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Merck & Co., Inc.
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Novartis International AG
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. Pfizer, Inc.
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. Sanofi
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Sun Pharmaceutical Industries, Ltd.
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. Teva Pharmaceutical Industries Ltd.
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. Viatris Inc.
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments

10. Global High Potency APIs Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. AbbVie
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Albany Molecular Research Inc.
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. BASF SE
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Bayer AG
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Boehringer Ingelheim International GmbH.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Bristol-Myers Squibb Company
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Carbogen Amcis
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Cipla Inc.
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Corden Pharma International
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. Dr. Reddy's Laboratories Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Eli Lilly and Company
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. F. Hoffmann-La Roche
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. Lonza
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Merck & Co., Inc.
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Novartis International AG
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. Pfizer, Inc.
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. Sanofi
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Sun Pharmaceutical Industries, Ltd.
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. Teva Pharmaceutical Industries Ltd.
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. Viatris Inc.
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제